← Back to Search

(68Ga)PSMA-HBED-CC for Prostate Cancer

Q: How many participants are being considered for inclusion in this clinical research?

Sign-ups for this particular research project have been closed. First published on July 14th 2016 and last edited on January 29th 2021, other trials may be more suitable if you are seeking to participate in a clinical study. Currently, 1252 studies related to <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> and 17 (68Ga)PSMA-HBED-CC trials are actively recruiting patients.

Q: Are there any opportunities for patients to participate in this clinical investigation currently?

Unfortunatley, the recruitment period for this clinical trial has concluded. It first went up on July 14th 2016 and was last edited on January 29th 2021. If you are looking to join another study there are currently 1252 trials seeking participants with <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> and 17 studies that require (68Ga)PSMA-HBED-CC patients.

Q: What medical issues does (68Ga)PSMA-HBED-CC typically address?

(68Ga)PSMA-HBED-CC has been approved for treating <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> and is also effective in managing skin disorders such as <a href="https://www.withpower.com/clinical-trials/eczema">eczema</a>, dyshidrotic, <a href="https://www.withpower.com/clinical-trials/psoriasis">psoriasis</a>, and neurodermatitis.

Phase < 1

Waitlist Available

Led By Janet Pollard, M.D.

Research Sponsored by Janet Pollard

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 60 minutes post-injection

Awards & highlights

Study Summary

This trial is looking at a new radiotracer, Ga-68 PSMA-HBED-CC, to see if it can detect metastatic prostate cancer early. Investigators will use a test and re-test design to see how well the radiotracer works.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 60 minutes post-injection

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~60 minutes post-injection

This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 minutes post-injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reproducibility assessment

Secondary outcome measures

Biodistribution assessment

Trial Design

1Treatment groups

Experimental Treatment

Group I: (68Ga)PSMA-HBED-CCExperimental Treatment1 Intervention

Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Janet PollardLead Sponsor

University of IowaLead Sponsor

446 Previous Clinical Trials

879,472 Total Patients Enrolled

2 Trials studying Prostate Cancer

62 Patients Enrolled for Prostate Cancer

Janet Pollard, M.D.Principal InvestigatorUniversity of Iowa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being considered for inclusion in this clinical research?

"Sign-ups for this particular research project have been closed. First published on July 14th 2016 and last edited on January 29th 2021, other trials may be more suitable if you are seeking to participate in a clinical study. Currently, 1252 studies related to prostate cancer and 17 (68Ga)PSMA-HBED-CC trials are actively recruiting patients."

Answered by AI

Are there any opportunities for patients to participate in this clinical investigation currently?

"Unfortunatley, the recruitment period for this clinical trial has concluded. It first went up on July 14th 2016 and was last edited on January 29th 2021. If you are looking to join another study there are currently 1252 trials seeking participants with prostate cancer and 17 studies that require (68Ga)PSMA-HBED-CC patients."

Answered by AI

What medical issues does (68Ga)PSMA-HBED-CC typically address?

"(68Ga)PSMA-HBED-CC has been approved for treating prostate cancer and is also effective in managing skin disorders such as eczema, dyshidrotic, psoriasis, and neurodermatitis."

Answered by AI

Recent research and studies

European Journal of Nuclear Medicine and Molecular ImagingJournal

The Diagnostic Value of PET/CT Imaging with the 68ga-labelled PSMA Ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer

Afshar-Oromieh, Ali, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, et al.. 2014. “The Diagnostic Value of PET/CT Imaging with the 68ga-labelled PSMA Ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer”. European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media LLC. doi:10.1007/s00259-014-2949-6.

TheranosticsJournal

Diagnostic Accuracy of Ga-68-hbed-cc-psma-ligand-pet/ct Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer

Jilg, Cordula A., Vanessa Drendel, H. Christian Rischke, Teresa Beck, Werner Vach, Kathrin Schaal, Ulrich Wetterauer, Wolfgang Schultze-Seemann, and Philipp T. Meyer. 2017. “Diagnostic Accuracy of Ga-68-hbed-cc-psma-ligand-pet/ct Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer”. Theranostics. Ivyspring International Publisher. doi:10.7150/thno.18421.

clinicaltrials.govStudy

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

Janet Pollard 2016. "Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02952469.